SCHEMBL22307673

SCHEMBL22307673

Nc1nc2ccc(CO)cn2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 8/20 0.39
PIK3CD O00329 7/20 0.39
PIK3CA P42336 6/20 0.39
PIK3CB P42338 2/20 0.39
TYR P14679 1/20 0.35
NUDT1 P36639 2/20 0.33
FYN P06241 1/20 0.33
MAP3K5 Q99683 1/20 0.32
MAP4K4 O95819 1/20 0.32
PAK4 O96013 1/20 0.32
CSF1R P07333 1/20 0.32
RET P07949 1/20 0.32
GRK5 P34947 1/20 0.32
MAPK8 P45983 1/20 0.32
CSNK1A1 P48729 1/20 0.32
ACVR1 Q04771 1/20 0.32
PTK2 Q05397 1/20 0.32
TYRO3 Q06418 1/20 0.32
MAP4K2 Q12851 1/20 0.32
DYRK1A Q13627 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25068511 0.82 PIK3CG (0.42) PIK3CGPIK3CDPIK3CAPIK3CBTLR9
SCHEMBL16808004 0.79 HSD17B10 (0.37) TYRFYNMAP3K5DYRK1A
SCHEMBL16781922 0.79 AHR (0.38) TYRFYNMAP3K5
SCHEMBL18727798 0.77 PIK3CG (0.42) PIK3CGPIK3CDPIK3CAPIK3CBNUDT1
SCHEMBL4325240 0.76 PIK3CG (0.42) PIK3CGPIK3CDPIK3CAPIK3CBNUDT1
SCHEMBL24656059 0.75 PIK3CG (0.43) PIK3CGPIK3CDPIK3CAPIK3CBNUDT1
Bromide SCHEMBL1260233 0.74 PIK3CG (0.41) PIK3CGPIK3CDPIK3CAPIK3CBNUDT1
SCHEMBL16781930 0.73 FFAR1 (0.49) FYNMAP3K5
SCHEMBL10044580 0.72 PIK3CG (0.44) PIK3CGPIK3CDPIK3CAPIK3CBNUDT1
SCHEMBL15415685 0.72 AHR (0.51) PIK3CGPIK3CDPIK3CAPIK3CBNUDT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223286-A1 IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF BETTA PHARMACEUTICALS CO.,LTD (CN) 2025-07-10 US disclosed
US-12187713-B2 Immunomodulators, compositions and methods thereof BETTA PHARMACEUTICALS CO., LTD (CN) 2025-01-07 US disclosed
US-20220098183-A1 IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF BETTA PHARMACEUTICALS CO LTD (CN) 2022-03-31 US disclosed
WO-2020156323-A1 IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF BETTA PHARMACEUTICALS CO., LTD (CN) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250223286-A1 IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF IL2, IL5, TSLP PIK3CG 2123/4885PIK3CD 2207/4885PIK3CA 2873/4885
US-20220098183-A1 IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF IL2, TSLP, CD74 PIK3CG 2009/4885PIK3CD 1907/4885PIK3CA 3087/4885
US-12187713-B2 Immunomodulators, compositions and methods thereof IL2, TSLP, CD74 PIK3CG 2009/4885PIK3CD 1907/4885PIK3CA 3087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.